Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

Rahul S Dalal; Lindsay M Clarke; Alex Carlin; Heidy Cabral; Jessica R Allegretti

doi:10.1093/ibd/izae215

Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

Inflamm Bowel Dis. 2024 Sep 19:izae215. doi: 10.1093/ibd/izae215. Online ahead of print.

Authors

Rahul S Dalal¹, Lindsay M Clarke¹, Alex Carlin¹, Heidy Cabral¹, Jessica R Allegretti¹

Affiliation

¹ Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 39301678
DOI: 10.1093/ibd/izae215

No abstract available

Keywords: bio-naïve; biologics; inflammatory bowel disease; ulcerative colitis.

Plain language summary

In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-naïve patients with ulcerative proctitis.

Grants and funding

Brigham and Women's Hospital Faculty Career Development Award